Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 20/20 | 0.71 |
| ▸ | BCL2L1 | Q07817 | 19/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21081681 | 0.95 | BCL2 (0.70) | BCL2BCL2L1 | |
| SCHEMBL23052593 | 0.94 | BCL2 (0.69) | BCL2BCL2L1 | |
| SCHEMBL23052582 | 0.94 | BCL2 (0.69) | BCL2BCL2L1 | |
| SCHEMBL21081684 | 0.91 | BCL2L1 (0.85) | BCL2BCL2L1 | |
| SCHEMBL30872028 | 0.91 | BCL2L1 (0.85) | BCL2BCL2L1 | |
| SCHEMBL2022204 | 0.90 | BCL2 (0.74) | BCL2BCL2L1 | |
| SCHEMBL19491795 | 0.90 | BCL2 (0.71) | BCL2BCL2L1 | |
| SCHEMBL21081683 | 0.88 | BCL2L1 (0.81) | BCL2BCL2L1 | |
| SCHEMBL25993105 | 0.87 | BCL2L1 (0.74) | BCL2BCL2L1 | |
| SCHEMBL21081703 | 0.87 | BCL2L1 (0.82) | BCL2BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11717574-B2 | Therapeutic dendrimers | ASTRAZENECA AB (SE) | 2023-08-08 | — | — | US | disclosed |
| US-20210060172-A1 | THERAPEUTIC DENDRIMERS | ASTRAZENECA AB (SE) | 2021-03-04 | — | — | US | disclosed |
| US-10314920-B2 | Therapeutic dendrimers | ASTRAZENECA AB (SE) | 2019-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10314920-B2 | Therapeutic dendrimers | CD44, ITGAV, FOLR1 | BCL2 1164/4885BCL2L1 2257/4885 |
| US-11717574-B2 | Therapeutic dendrimers | CD44, ITGAV, FOLR1 | BCL2 1164/4885BCL2L1 2257/4885 |
| US-20210060172-A1 | THERAPEUTIC DENDRIMERS | CD44, ITGAV, FOLR1 | BCL2 1164/4885BCL2L1 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.